Literature DB >> 20165818

Validation of new prognostic and predictive scores by sequential testing approach.

Carsten Nieder1, Ellinor Haukland, Adam Pawinski, Astrid Dalhaug.   

Abstract

BACKGROUND AND
PURPOSE: For practitioners, the question arises how their own patient population differs from that used in large-scale analyses resulting in new scores and nomograms and whether such tools actually are valid at a local level and thus can be implemented. A recent article proposed an easy-to-use method for the in-clinic validation of new prediction tools with a limited number of patients, a so-called sequential testing approach. The present study evaluates this approach in scores related to radiation oncology.
MATERIAL AND METHODS: Three different scores were used, each predicting short overall survival after palliative radiotherapy (bone metastases, brain metastases, metastatic spinal cord compression). For each scenario, a limited number of consecutive patients entered the sequential testing approach (Table 1). The positive predictive value (PPV) was used for validation of the respective score and it was required that the PPV exceeded 80%.
RESULTS: For two scores, validity in the own local patient population could be confirmed after entering 13 and 17 patients, respectively (Figures 1 and 3). For the third score, no decision could be reached even after increasing the sample size to 30 (Figure 2).
CONCLUSION: In-clinic validation of new predictive tools with sequential testing approach should be preferred over uncritical adoption of tools which provide no significant benefit to local patient populations. Often the necessary number of patients can be reached within reasonable time frames even in small oncology practices. In addition, validation is performed continuously as the data are collected.

Entities:  

Mesh:

Year:  2010        PMID: 20165818     DOI: 10.1007/s00066-010-2095-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  8 in total

1.  Two new prognostic indices for brain metastases--where do we go from here?

Authors:  Carsten Nieder
Journal:  Strahlenther Onkol       Date:  2008-09       Impact factor: 3.621

2.  External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: time trends, outcome, and risk stratification.

Authors:  Yasuo Yoshioka; Osamu Suzuki; Kana Kobayashi; Teruki Teshima; Yuji Yamada; Tadayuki Kotsuma; Masahiko Koizumi; Kazufumi Kagawa; Masashi Chatani; Shigetoshi Shimamoto; Eiichi Tanaka; Hideya Yamazaki; Takehiro Inoue
Journal:  Strahlenther Onkol       Date:  2009-08-28       Impact factor: 3.621

3.  A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases.

Authors:  Dirk Rades; Juergen Dunst; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2008-05       Impact factor: 3.621

4.  Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.

Authors:  Kathrin Dellas; Matthias Bache; Steffi U Pigorsch; Helge Taubert; Matthias Kappler; Daniel Holzapfel; Ester Zorn; Hans-Juergen Holzhausen; Gabriele Haensgen
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

5.  Sequential testing approach as an efficient and easier alternative for the validation of new predictive technologies in the clinic.

Authors:  Craig A Beam; Weihua Gao; Virgilia Macias; Weimin Liang; André Kajdacsy Balla
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

6.  Prognostic factors and a scoring system for survival after radiotherapy for metastases to the spinal column: a review of 544 patients at Shizuoka Cancer Center Hospital.

Authors:  Masashi Mizumoto; Hideyuki Harada; Hirofumi Asakura; Takayuki Hashimoto; Kazuhisa Furutani; Haruko Hashii; Tatsuya Takagi; Hirohisa Katagiri; Mitsuru Takahashi; Tetsuo Nishimura
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

7.  The first score predicting overall survival in patients with metastatic spinal cord compression.

Authors:  Dirk Rades; Juergen Dunst; Steven E Schild
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

8.  Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.

Authors:  Marc D Piroth; Bernd Gagel; Michael Pinkawa; Sven Stanzel; Branka Asadpour; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

  8 in total
  5 in total

1.  Metastatic spinal cord compression: a validated survival score for elderly patients.

Authors:  Dirk Rades; Jasmin N Evers; Amira Bajrovic; Theo Veninga; Johann H Karstens; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2014-03-22       Impact factor: 3.621

2.  Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis.

Authors:  Dirk Rades; Annika Panzner; Volker Rudat; Johann H Karstens; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

3.  Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies.

Authors:  C Nieder; N H Andratschke; H Geinitz; A L Grosu
Journal:  Strahlenther Onkol       Date:  2012-04-26       Impact factor: 3.621

4.  Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors.

Authors:  P C Lara; M Lloret; A Valenciano; B Clavo; B Pinar; A Rey; L A Henríquez-Hernández
Journal:  Strahlenther Onkol       Date:  2012-11-01       Impact factor: 3.621

5.  The Usefulness of Prognostic Tools in Breast Cancer Patients with Brain Metastases.

Authors:  Joanna Kufel-Grabowska; Anna Niwińska; Barbara S Radecka; Shan Ali; Tomasz Mandat; Renata Duchnowska
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.